Form 4: Cytek Biosciences Officer Yan Ming Reports Stock Transactions

Cytek Biosciences' Chief Technology Officer, Yan Ming, reports the vesting of restricted stock units and subsequent tax withholding.

Summary

• On March 10, 2025, Yan Ming, Chief Technology Officer of Cytek Biosciences, Inc., reported transactions involving common stock and restricted stock units (RSUs).
• Yan Ming acquired 9,817 shares of common stock through the vesting of RSUs and disposed of 2,911 shares to cover tax obligations at a price of $4.36 per share, resulting in a net increase in holdings.
• Additionally, 7,366 shares were acquired through RSU vesting, with 2,185 shares disposed of for tax purposes at $4.36 per share.
• Following these transactions, Yan Ming directly owns 6,031,802 shares of Cytek Biosciences common stock and 66,302 restricted stock units.

Sentiment

Score: 5

Explanation: This is a neutral report on insider transactions related to compensation. It doesn't inherently indicate positive or negative sentiment about the company's performance.

Industry Context

This Form 4 filing is a routine disclosure required by the SEC for insiders of publicly traded companies, providing transparency into their trading activities. It's a standard practice and doesn't necessarily indicate a change in the company's outlook.

Comparison to Industry Standards

• Form 4 filings are standard practice for publicly traded companies and their insiders.
• The vesting schedule of the RSUs (2/48, 3/48, 3/48, 4/48 over four years) is a common vesting structure.
• Tax withholding through share surrender is a typical method for covering tax obligations related to RSU vesting.

Stakeholder Impact

• The transactions have a minimal direct impact on stakeholders, as they are related to executive compensation and tax obligations.
• The filing provides transparency to shareholders regarding insider transactions.

Key Dates